Where can I buy cabozantinib and how to buy it in China?

Cabozantinib (Cabozantinib) is a kinase inhibitor mainly used to treat patients including thyroid cancer, thyroid-like cancer, renal cancer and hepatocellular carcinoma. The drug has been marketed in overseas countries such as the United States and the European Union, but as of 2024, it has not yet obtained marketing approval in China, and domestic patients cannot yet purchase the drug in domestic hospitals or pharmacies.

Cabotinib can exert anti-tumor effects by inhibiting the activity of multiple tyrosine kinase receptors, such asRET, MET, VEGFR, etc. It can stimulate tumor cells, reduce metastasis and inhibit tumor angiogenesis. In addition, there are some adverse reactions and abnormal laboratory indicators when using cabozantinib, such as diarrhea, stomatitis, palmoplantar erythrodysesthesia syndrome, etc., as well as increases in aspartate aminotransferase and alanine aminotransferase. Therefore, before using this drug, patients need to fully understand its indications, usage and dosage, adverse reactions and other information, and use the drug strictly in accordance with the doctor's guidance and recommendations.

Regarding the purchase of cabozantinib, here are some possible ways: Patients can obtain cabozantinib through international purchases. This may need to be purchased through overseas pharmacies, medical institutions or online platforms. It should be noted that there are certain risks in international purchases, such as drug quality, transportation safety and other issues. Therefore, it is recommended to fully understand relevant information and choose reliable channels before purchasing.

Sometimes, patients can get access to drugs that are not yet available in China by participating in clinical trials. This requires that the patient meets the enrollment criteria for a clinical trial and that the trial drug happens to be cabozantinib. Participation in a clinical trial may require some time and effort, but it may be a viable option for patients who do not have access to other treatment options.